Sugi Predict

Sugi Predict / Targets / CPS1

CPS1

Carbamoyl-phosphate synthase [ammonia], mitochondrial · P31327 · CPS1 on Sugi Atlas →

5,445 patent compounds predicted against CPS1, 1,783 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL3854933 SCHEMBL3854933 0.50 19/20
SCHEMBL2645086 SCHEMBL2645086 0.39 18/20
SCHEMBL7874316 SCHEMBL7874316 0.62 17/20
SCHEMBL2644031 SCHEMBL2644031 0.41 16/20
SCHEMBL2644034 SCHEMBL2644034 0.41 16/20
SCHEMBL2644060 SCHEMBL2644060 0.41 16/20
SCHEMBL2645627 SCHEMBL2645627 0.40 16/20
SCHEMBL1555099 SCHEMBL1555099 0.61 15/20
SCHEMBL3502022 SCHEMBL3502022 0.58 15/20
SCHEMBL4887092 SCHEMBL4887092 0.52 15/20
SCHEMBL1003506 SCHEMBL1003506 0.58 14/20
SCHEMBL7876941 SCHEMBL7876941 0.56 14/20
SCHEMBL1691191 SCHEMBL1691191 0.55 14/20
SCHEMBL2669286 SCHEMBL2669286 0.34 14/20
SCHEMBL2324673 SCHEMBL2324673 0.59 13/20
SCHEMBL7871468 SCHEMBL7871468 0.57 13/20
SCHEMBL531476 SCHEMBL531476 0.54 13/20
SCHEMBL2644322 SCHEMBL2644322 0.41 13/20
SCHEMBL2644328 SCHEMBL2644328 0.41 13/20
SCHEMBL2644380 SCHEMBL2644380 0.41 13/20

Clinical trials — most relevant to CPS1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
N-Carbamylglutamate (Carbaglu) In The Treatment Of Hyperammonemia PHASE2/PHASE3UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
A Phase I/II Open-label Safety and Efficacy Study of LNP.UCD.ABE in Patients With Urea Cycle Disorders. PHASE1/PHASE2NOT_YET_RECRUITING
Metabolic Cofactor Supplementation in Alzheimer's Disease (AD) and Parkinson's Disease (PD) Patients PHASE2COMPLETED
A Study of Bezafibrate in Mitochondrial Myopathy PHASE2COMPLETED
Metabolic Cofactor Supplementation in Obese Patients With Non-Alcoholic Fatty Liver Disease PHASE2COMPLETED
Acetylcarnitine and Insulin Sensitivity PHASE2COMPLETED
Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate PHASE2WITHDRAWN
Therapeutic Efficacy of L-Ornithine L-Aspartate Infusion in Patients With Acute Liver Failure PHASE2UNKNOWN
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers PHASE1COMPLETED
Multi-omics Study in Citrin Deficiency nanACTIVE_NOT_RECRUITING
Nitric Oxide Supplementation on Neurocognitive Functions in Patients With ASLD nanCOMPLETED
Tissue Sample Study for Mitochondrial Disorders nanENROLLING_BY_INVITATION
11C-Acetate PET/CT Non-FDG-Avid Tumors nanUNKNOWN
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Nephroprotective Effects of Carnitine and (PDE5) Inhibitor Agent Against Contrast Media-induced Nephropathy (CMN) nanUNKNOWN
Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders nanCOMPLETED
Effect of Sulfur Amino Acid Depletion and Acetaminophen on Plasma Glutatione nanCOMPLETED
LIPCAR, Cuproptosis, and Α-SMA in the Pathogenesis of AMI and Remodeling nanNOT_YET_RECRUITING
Lifestyle Intervention in Preparation for Pregnancy (LIPP) nanCOMPLETED
Triheptanoin (UX007) to Treat Citrate Transporter Deficiency nanNO_LONGER_AVAILABLE
Mitoquines in COPD nanUNKNOWN
Effect of Branched Chain Amino Acids on Muscle nanCOMPLETED
Chronic Liver Disease in Urea Cycle Disorders nanCOMPLETED
Drug Repurposing for Mitochondrial Disorders Using iPSCs Derived Neural Cells nanRECRUITING
Natural History Study of FDXR Mutation-related Mitochondriopathy nanCOMPLETED
Plasma Cytochrome c as Biomarker of Traumatic Injury and Predictor of Outcome nanCOMPLETED
Fatty Acid Oxidation Defects and Insulin Sensitivity nanCOMPLETED
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance nanCOMPLETED
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CPS1 binder may also engage these)

ProteinNameSimilarity
Q8C196 — 1.000 Q8C196 →
P07756 — 1.000 P07756 →
P07259 — 1.000 P07259 →
Q7S8A6 — 1.000 Q7S8A6 →
P46056 — 1.000 P46056 →
Q91293 — 0.998 Q91293 →
O94313 — 0.998 O94313 →
P35007 — 0.997 P35007 →
B2RQC6 — 0.997 B2RQC6 →
P05990 — 0.997 P05990 →
P20054 — 0.997 P20054 →
P50246 — 0.997 P50246 →
O23255 — 0.997 O23255 →
O80988 — 0.997 O80988 →
O93937 — 0.996 O93937 →
Q01781 — 0.996 Q01781 →
Q07YC9 — 0.996 Q07YC9 →
P09440 — 0.996 P09440 →
Q0U5H7 — 0.995 Q0U5H7 →
Q9QSK1 — 0.995 Q9QSK1 →
Q6MPZ6 — 0.995 Q6MPZ6 →
Q5FJY2 — 0.995 Q5FJY2 →
Q75D66 — 0.995 Q75D66 →
P34203 — 0.995 P34203 →
Q32RI0 — 0.995 Q32RI0 →
P83773 — 0.995 P83773 →
Q03940 — 0.995 Q03940 →
Q5A0W7 — 0.995 Q5A0W7 →
O60060 — 0.995 O60060 →
Q2H132 — 0.994 Q2H132 →